Targeting the Main Protease of SARS‐CoV‐2: From the Establishment of High Throughput Screening to the Design of Tailored Inhibitors
作者:Julian Breidenbach、Carina Lemke、Thanigaimalai Pillaiyar、Laura Schäkel、Ghazl Al Hamwi、Miriam Diett、Robin Gedschold、Nina Geiger、Vittoria Lopez、Salahuddin Mirza、Vigneshwaran Namasivayam、Anke C. Schiedel、Katharina Sylvester、Dominik Thimm、Christin Vielmuth、Lan Phuong Vu、Maria Zyulina、Jochen Bodem、Michael Gütschow、Christa E. Müller
DOI:10.1002/anie.202016961
日期:2021.4.26
The main protease of SARS‐CoV‐2 (Mpro), the causative agent of COVID‐19, constitutes a significant drug target. A new fluorogenic substrate was kinetically compared to an internally quenched fluorescent peptide and shown to be ideally suitable for high throughput screening with recombinantly expressed Mpro. Two classes of protease inhibitors, azanitriles and pyridyl esters, were identified, optimized
SARS-CoV-2 (M pro ) 的主要蛋白酶是 COVID-19 的病原体,是一个重要的药物靶点。一种新的荧光底物与内部淬灭的荧光肽进行了动力学比较,结果表明它非常适合用重组表达的 M pro进行高通量筛选。两类蛋白酶抑制剂,氮腈和吡啶酯,经过鉴定、优化并进行了深入的生化表征。配备独特氮腈弹头的定制肽同时抑制 M pro和组织蛋白酶 L(一种与病毒细胞进入相关的蛋白酶)。通过位置扫描分析吡啶基吲哚酯。事实证明,我们针对 M pro抑制剂的重点方法优于虚拟筛选。使用两种不可逆抑制剂,氮腈8 (k inac /K=37 500 m -1 s -1 , K=24.0 nm ) 和吡啶酯17 (k inac /K=29 100 m -1 s -1 , K=10.0 nm ),已经发现了有希望进一步开发的候选药物。